Company Description
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders.
The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial.
It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial.
Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan.
The company was incorporated in 2014 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2014 |
| IPO Date | Oct 9, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 29 |
| CEO | Dr. Javier Szwarcberg M.D., M.P.H. |
Contact Details
Address: 611 Gateway Boulevard, Suite 740 South San Francisco, California 94080 United States | |
| Phone | (415) 655-4168 |
| Website | sprucebiosciences.com |
Stock Details
| Ticker Symbol | SPRB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001683553 |
| CUSIP Number | 85209E109 |
| ISIN Number | US85209E1091 |
| Employer ID | 81-2154263 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael G. Grey | Executive Chairman |
| Dr. Javier Szwarcberg M.D., M.P.H. | Chief Executive Officer and Director |
| Samir M. Gharib C.P.A., M.B.A. | President and Chief Financial Officer |
| Dr. Ralph William Charlton III, M.D. | Chief Medical Officer |
| P. J. Ramtin | Senior Vice President of Business Operations |
| Heidi Petersen M.P.H. | Senior Vice President of Regulatory and Quality |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 25, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Apr 5, 2024 | ARS | Filing |
| Apr 5, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 5, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 28, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 28, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Mar 25, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 20, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 18, 2024 | 144 | Filing |
| Mar 18, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |